Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Aim: The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” replaces
the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

Importance Anthracyclines treat a broad range of cancers. Basic and retrospective clinical
data have suggested that use of atorvastatin may be associated with a reduction in cardiac …

Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed
world. Evidence increasingly shows that these conditions are interlinked through common …

Cardiotoxicity is a feared side effect that may limit the clinical use of anthracyclines. It may
indeed affect the quality of life and survival of patients with cancer, regardless of oncological …

1–«МНОЦ МГУ им. МВ Ломоносова», 119192, Москва, Ломоносовский пр-кт, д. 27, корп.
10 2–ФГБОУ ВО «ПИМУ» МЗ РФ, 603950, Нижний Новгород, пл. Минина и Пожарского …

Reactive oxygen species (ROS) are highly reactive chemical species containing oxygen,
controlled by both enzymatic and nonenzymatic antioxidant defense systems. In the heart …

Anthracycline chemotherapy maintains a prominent role in treating many forms of cancer.
Cardiotoxic side effects limit their dosing and improved cancer outcomes expose the cancer …